| URN | urn:agi-llid:6720 |
|---|---|
| Total Entities | 0 |
| Connectivity | 1200 |
| Name | Srebf1 |
| Description | sterol regulatory element-binding transcription factor 1 |
| Notes | 2 years after bilio-pancreatic diversion the degree of fat mass loss seems to interfere with regulatory binding protein 1c (SREBP-1c)gene suppression to preserve an adequate amount of fat storage 2 years after bilio-pancreatic diversion the degree of fat mass loss seems to interfere with regulatory binding protein 1c (SREBP-1c)gene suppression to preserve an adequate amount of fat storage. APOA5 gene expression is regulated by the LXR ligand T0901317 in a negative manner through SREBP-1c. EC nuclei showed strong SREBP staining in human atherosclerotic lesions, suggesting a role for SREBP. Endothelial cholesterol depletion & SREBP activation play a role in inflammatory processes in which phospholipid oxidation products accumulate. High levels of SREBP-1 protein is associted with during prostate cancer progression to androgen independence. Phagocytosis triggered the proteolytic activation of SREBP-1a and SREBP-2; upon overexpression of these proteins, phagocytosis-induced transcription and lipid synthesis were blocked; SREBPs are essential regulators of membrane biogenesis. Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Role of the SREBF-1 gene in genetic predisposition of metabolic diseases such as obesity, type 2 diabetes, and dyslipidemia. SREBP-1 has a novel role as negative regulator of gluconeogenic genes through a cross-talk with HNF-4alpha interference with PGC-1 recruitment. SREBP-1 has a role in the species differential regulation of cholesterol and bile acid homeostasis via a novel mechanism of up-regulation of the hSHP gene expression. SREBP-1 homodimers and heterodimers localize in the nucleus and activate transcription. SREBP-1 not necessary for hepatic Akt-mediated hypoglycemic effect. Myr-Akt-induced hypertriglyceridemia and hepatic triglyceride accumulation mediated by Akt-induced SREBP-1 expression and mechanism involving fatty acid synthesis independent of SREBP-1. SREBP-1a and the CRE-bound proteins are essential for the SREBP-dependent response. SREBP-1ac mRNA was detectable in all tissues studied, although at lower levels than the major SREBP-1a & -1c isoforms. Transcription of SREBP-1ac mRNA was detectable in all tissues studied, although at lower levels than the major SREBP-1a & -1c isoforms. SREBP-1c and Sp1 interact to regulate transcription of the gene for phosphoenolpyruvate carboxykinase (GTP) in the liver. SREBP-1c gene is a candidate for human insulin resistance and a variant might influence diabetes risk. SREBP-1c is involved in the effect of insulin on HKII gene transcription. SREBP1a and APOB have roles in total and low-density lipoprotein cholesterol levels in patients with coronary artery disease. Sphinglipids in endocytic compartments serve as a ""molecular trap"" for cholesterol, leading to a reduction in cholesterol at the endoplasmic reticulum, induction of sterol regulatory element-binding protein-1 cleavage, and up-regulation of LDL receptors. Tethered SREBP-1a and -2 homodimers, similar to the monomeric forms, activated target genes more robustly than tethered SREBP-1c homodimers. This gene encodes a transcription factor that binds to the sterol regulatory element-1 (SRE1), which is a decamer flanking the low density lipoprotein receptor gene and some genes involved in sterol biosynthesis. The protein is synthesized as a precursor that is attached to the nuclear membrane and endoplasmic reticulum. Following cleavage, the mature protein translocates to the nucleus and activates transcription by binding to the SRE1. Sterols inhibit the cleavage of the precursor, and the mature nuclear form is rapidly catabolized, thereby reducing transcription. The protein is a member of the basic helix-loop-helix-leucine zipper (bHLH-Zip) transcription factor family. This gene is located within the Smith-Magenis syndrome region on chromosome 17. Two transcript variants encoding different isoforms have been found for this gene. This review shows how SREBP-1 might play a role in the development of cellular features belonging to lipotoxicity and, possibly, syndrome X. Transfected from humans into transgenic mice, SREBP-1c and endogenous lipogenesis could be involved in beta-cell dysfunction and diabetes. Transgenic SHR overexpressing SREBP-1a is nonobese rat model of fatty liver, disordered glucose and lipid metabolism, and hypertension. Possible model for studying pathogenesis and treatment of metabolic syndrome associated with hepatic steatosis. While the SREBP-1a and -1c isoforms differentially activate transcription, the molecular basis of this difference is unknown. Here we define the differences between these proteins that confer the enhanced activity of SREBP-1a. A strong graded interaction between SREBF-1a -36del/G genotypes and response of plasma apoA-I to treatment with fluvastatin. Activation of SREBP-1 by Akt leads to the induction of key enzymes of the cholesterol and fatty acid biosynthesis pathways, and thus membrane lipid biosynthesis. Effect of SREBP-1a expression on lipid metabolism at the level of the cellular protein network and the protein pattern of mitochondria. Expression altered in obesity and niddm. Expression of SREBP-1 is affected by polyunsaturated fatty acids in human cells. HCG and insulin cause a switch toward expression of the SREBP-1c isoform with consequent effects on fatty acid synthesis in culturred ganulosa cells (SRESBP-1c). May play discrete role in the regulation of the resistin gene expression. Molecular cloning of promoter; studies suggest that PDX-1 and HNF-4 both stimulate SREBP-1c gene expression. NSREBPs are essential for high levels of lipid synthesis in the liver and indicate that Insig's modulate nSREBP levels by binding and retaining SCAP in the ER. Results provide evidence that insulin action on sterol regulatory element binding protein (SREBP)-1c is dysregulated in adipose tissue from type 2 diabetic subjects. The SREBP-1c.BETA2.E47 complex is in a DNA looping structure which is required for efficient recruitment of CREB-binding protein/p300. Transcriptional activities to different target promoters of lipogenic and cholesterogenic genes. |
| Ariadne Ontology | Ubiquitous bHLH-ZIP factors |
|---|---|
| Secreted proteins | |
| Biofluids assayable substances |
| GO Molecular Function | chromatin binding |
|---|---|
| protein complex binding | |
| protein kinase binding | |
| DNA binding | |
| sequence-specific DNA binding | |
| sterol response element binding | |
| sequence-specific DNA binding transcription factor activity |
| GO Cellular Component | membrane |
|---|---|
| Golgi membrane | |
| endoplasmic reticulum membrane | |
| ER to Golgi transport vesicle membrane | |
| nuclear envelope | |
| integral to membrane | |
| protein complex | |
| cytoplasmic part | |
| cytoplasm | |
| cytoplasmic vesicle | |
| endoplasmic reticulum | |
| Golgi apparatus | |
| intracellular membrane-bounded organelle | |
| nucleus |
| GO Biological Process | negative regulation of insulin secretion |
|---|---|
| regulation of insulin secretion | |
| cellular response to starvation | |
| insulin receptor signaling pathway | |
| SREBP signaling pathway | |
| positive regulation of transcription, DNA-dependent | |
| positive regulation of triglyceride biosynthetic process | |
| positive regulation of fatty acid biosynthetic process | |
| positive regulation of transcription from RNA polymerase II promoter | |
| positive regulation of histone deacetylation | |
| negative regulation of transcription from RNA polymerase II promoter | |
| regulation of transcription, DNA-dependent | |
| regulation of transcription from RNA polymerase II promoter | |
| regulation of fatty acid metabolic process | |
| transcription, DNA-dependent | |
| cellular response to insulin stimulus | |
| response to drug | |
| response to food | |
| response to organic cyclic compound | |
| response to lipid | |
| response to peptide hormone stimulus | |
| response to progesterone stimulus | |
| response to insulin stimulus | |
| response to glucagon stimulus | |
| response to glucose stimulus | |
| response to cAMP | |
| response to fatty acid | |
| response to retinoic acid | |
| regulation of heart rate by chemical signal | |
| positive regulation of cholesterol biosynthetic process | |
| aging | |
| lung development | |
| lipid metabolic process | |
| lipid biosynthetic process | |
| steroid metabolic process | |
| cholesterol metabolic process |
| Pathway | Nuclear Envelope |
|---|---|
| Cleavage of Lamina in Apoptosis | |
| IGF1R -> ELK-SRF/HIF1A/MYC/SREBF signaling | |
| InsulinR -> ELK-SRF/SREBF signaling | |
| FibronectinR -> AP-1/ELK-SRF/SREBF signaling | |
| Fibronectin Expression Targets | |
| IGF1/STAT Expression Targets | |
| Insulin/ELK-SRF/HIF1A/MYC/SREBF Expression Targets | |
| Insulin/STAT Expression Targets | |
| EGF/AP-1/ATF Expression Targets | |
| EGF/STAT Expression Targets | |
| IGF1/ELK-SRF/HIF1A/MYC/SREBF Expression Targets | |
| IGF1/MEF/MYOD/MYOG Expression Targets | |
| Insulin/CEBPA/CTNNB/FOXA/FOXO Expression Targets | |
| Insulin/MEF/MYOD Expression Targets | |
| EGF/CTNN Expression Targets | |
| drug-gene, gene-chemical, gene-gene interaction pathway | |
| losartan_expanded2 | |
| losartan_expanded3 | |
| losartan-gene, gene-chemical, gene-gene interaction pathway | |
| sterol regulatory element-binding protein signaling pathway | |
| losartan-gene, gene-chemical, gene-gene interaction pathway | |
| losartan-gene, gene-chemical, gene-gene interaction pathway |
| Group | Ubiquitous bHLH-ZIP factors |
|---|---|
| negative regulation of insulin secretion | |
| regulation of insulin secretion | |
| cellular response to starvation | |
| insulin receptor signaling pathway | |
| SREBP signaling pathway | |
| positive regulation of transcription, DNA-dependent | |
| positive regulation of triglyceride biosynthetic process | |
| positive regulation of fatty acid biosynthetic process | |
| positive regulation of transcription from RNA polymerase II promoter | |
| positive regulation of histone deacetylation | |
| negative regulation of transcription from RNA polymerase II promoter | |
| regulation of transcription, DNA-dependent | |
| regulation of transcription from RNA polymerase II promoter | |
| regulation of fatty acid metabolic process | |
| transcription, DNA-dependent | |
| cellular response to insulin stimulus | |
| response to drug | |
| response to food | |
| response to organic cyclic compound | |
| response to lipid | |
| response to peptide hormone stimulus | |
| response to progesterone stimulus | |
| response to insulin stimulus | |
| response to glucagon stimulus | |
| response to glucose stimulus | |
| response to cAMP | |
| response to fatty acid | |
| response to retinoic acid | |
| regulation of heart rate by chemical signal | |
| positive regulation of cholesterol biosynthetic process | |
| aging | |
| lung development | |
| lipid metabolic process | |
| lipid biosynthetic process | |
| steroid metabolic process | |
| cholesterol metabolic process | |
| chromatin binding | |
| protein complex binding | |
| protein kinase binding | |
| DNA binding | |
| sequence-specific DNA binding | |
| sterol response element binding | |
| sequence-specific DNA binding transcription factor activity | |
| membrane | |
| Golgi membrane | |
| endoplasmic reticulum membrane | |
| ER to Golgi transport vesicle membrane | |
| nuclear envelope | |
| integral to membrane | |
| protein complex | |
| cytoplasmic part | |
| cytoplasm | |
| cytoplasmic vesicle | |
| endoplasmic reticulum | |
| Golgi apparatus | |
| intracellular membrane-bounded organelle | |
| nucleus | |
| Secreted proteins | |
| Biofluids assayable substances |
| MedScan ID | 6720 |
|---|
| Hugo ID | 11289 |
|---|
| Human chromosome position | 17p11.2 |
|---|
| LocusLink ID | 6720 |
|---|---|
| 20787 | |
| 78968 | |
| 216809 | |
| 276754 |
| Alias | SREBP1 |
|---|---|
| bHLHd1 | |
| SREBP-1c | |
| sterol regulatory element-binding protein 1 | |
| SREBP-1 | |
| class D basic helix-loop-helix protein 1 | |
| ADD1 | |
| ADD-1 | |
| SREBP1c | |
| SREBP-1a | |
| D630008H06 | |
| RP23-456O18.1 | |
| adipocyte determination- and differentiation-dependent factor 1 | |
| sterol regulatory element binding factor 1 | |
| sterol regulatory element-binding transcription factor 1 | |
| sterol response element-binding protein I | |
| SREBP-1/ADD1 | |
| sterol regulatory element binding factor I | |
| sterol regulatory element binding protein | |
| SREBP I | |
| Sterol regulatory element binding protein-1 | |
| sterol regulatory element binding transcription factor I | |
| sterol regulatory element-binding protein | |
| sterol response element binding protein | |
| sterol response element binding protein 1 | |
| sterol response element binding protein-1 | |
| SREBP | |
| sterol response element-binding protein 1 | |
| Sterol regulatory element binding protein I | |
| sterol response element-binding protein-1 | |
| sterol response element-binding protein-1c | |
| sterol responsive element-binding protein-1c | |
| sterol response element-binding protein | |
| sterol regulatory element binding transcription factor 1 | |
| SRE-binding protein-1c | |
| ADD1/SREBP | |
| ADD1/SREBP-1c | |
| LOC124554 | |
| LOC276754 | |
| OTTHUMP00000065591 | |
| SREBF1 | |
| SRE-binding factor I | |
| ADD1/SREBP-1 | |
| OTTHUMP00000065592 | |
| SRE-binding protein-1a | |
| SRE-binding factor 1 | |
| Srebf I | |
| OTTMUSP00000005987 | |
| OTTMUSP00000005986 | |
| OTTMUSP00000005985 | |
| OTTHUMP00000065593 | |
| Srebf1s | |
| SREBP1s | |
| Srebf Is | |
| SREBP Is |
| Organism | Homo sapiens |
|---|---|
| Mus musculus | |
| Rattus norvegicus |
| OMIM ID | 184756 |
|---|
| Unigene ID | Hs.592123 |
|---|---|
| Hs.733635 | |
| Mm.278701 | |
| Rn.198857 | |
| Rn.221929 | |
| Mm.296366 | |
| Rn.217688 | |
| Rn.801 | |
| Rn.95306 | |
| Hs.554776 | |
| Hs.190284 |
| KEGG ID | hsa:6720 |
|---|---|
| mmu:20787 | |
| rno:78968 |
| Swiss-Prot Accession | P36956 |
|---|---|
| Q9WTN3 | |
| P56720 | |
| D3DXC4 | |
| Q16062 | |
| Q59F52 | |
| Q6P4R7 | |
| Q6PFW7 | |
| Q6PJ36 | |
| Q8TAK9 | |
| Q99PI6 | |
| Q99PI7 | |
| Q3U458 | |
| Q3UDJ3 | |
| Q5SRX5 | |
| Q8C733 | |
| Q99JK7 | |
| Q3TYX1 | |
| Q5SRX6 |
| GO ID | 0003677 |
|---|---|
| 0003682 | |
| 0019901 | |
| 0043565 | |
| 0003700 | |
| 0032810 | |
| 0007568 | |
| 0009267 | |
| 0008203 | |
| 0008286 | |
| 0008610 | |
| 0006629 | |
| 0030324 | |
| 0046676 | |
| 0000122 | |
| 0045542 | |
| 0031065 | |
| 0045944 | |
| 0010867 | |
| 0019217 | |
| 0003062 | |
| 0006357 | |
| 0051591 | |
| 0042493 | |
| 0070542 | |
| 0032094 | |
| 0033762 | |
| 0009749 | |
| 0032570 | |
| 0032526 | |
| 0006351 | |
| 0012507 | |
| 0000139 | |
| 0044444 | |
| 0005783 | |
| 0005789 | |
| 0016021 | |
| 0005635 | |
| 0005634 | |
| 0043234 | |
| 0032403 | |
| 0032933 | |
| 0045723 | |
| 0045893 | |
| 0050796 | |
| 0006355 | |
| 0008202 | |
| 0005794 | |
| 0005737 | |
| 0031410 | |
| 0043231 | |
| 0016020 | |
| 0032869 | |
| 0032868 | |
| 0033993 | |
| 0014070 | |
| 0043434 | |
| 0035104 | |
| 0003702 | |
| 0003704 | |
| 0030528 | |
| 0043193 | |
| 0045941 | |
| 0045449 | |
| 0006350 | |
| 0005792 | |
| 0005515 | |
| 0005795 |
| PIR ID | A48845 |
|---|---|
| PD0035 |
| Swiss-Prot ID | SRBP1_HUMAN |
|---|---|
| SRBP1_RAT | |
| SRBP1_MOUSE | |
| D3DXC4_HUMAN |
| Cell Localization | Endoplasmic reticulum membrane |
|---|---|
| Golgi apparatus membrane | |
| Cytoplasmic vesicle | |
| COPII-coated vesicle membrane | |
| Nucleus |
| IPI ID | IPI00220878 |
|---|---|
| IPI00418428 | |
| IPI00419318 | |
| IPI00795043 | |
| IPI00560536 | |
| IPI00562316 | |
| IPI00223219 | |
| IPI00226436 | |
| IPI00387320 | |
| IPI00750980 | |
| IPI00796121 | |
| IPI00796977 | |
| IPI00797516 | |
| IPI00764709 | |
| IPI00369557 | |
| IPI00778258 |
| Mouse chromosome position | 11 |
|---|---|
| 11 B2 |
| Rat chromosome position | 10q22 |
|---|
| Homologene ID | 3079 |
|---|
| MGI ID | 107606 |
|---|
| RGD ID | 69423 |
|---|
| Primary Cell Localization | Nucleus |
|---|
| KEGG pathway | Insulin signaling pathway |
|---|